Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.

Manuel Galan-GutierrezPilar Font-UgaldeLaura PadillaCarlos Hernandez-MontoyaDaniel GodoyJose C Armario-HitaRicardo Ruiz Villaverde

Published in: International journal of dermatology (2022)

Brodalumab showed excellent results in the control of psoriasis in the mid-term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical practice
peritoneal dialysis
prognostic factors
patient reported outcomes